Cargando…

Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients

BACKGROUND: The aim of the present analysis was to evaluate the recurrence pattern in patients with recurrent malignant glioma after re-irradiation in combination with bevacizumab as there is limited data on how to optimally choose dose, fractionation and delineation margins. METHODS: Thirty-one pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niyazi, Maximilian, Jansen, Nathalie Lisa, Rottler, Maya, Ganswindt, Ute, Belka, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307885/ https://www.ncbi.nlm.nih.gov/pubmed/25529015 http://dx.doi.org/10.1186/s13014-014-0299-y

Ejemplares similares

Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation
por: Fleischmann, Daniel F., et al.
Publicado: (2019)

Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma
por: Niyazi, Maximilian, et al.
Publicado: (2013)

Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort
por: Niyazi, Maximilian, et al.
Publicado: (2014)

Recurrence pattern analysis after [(68)Ga]-DOTATATE-PET/CT -planned radiotherapy of high-grade meningiomas
por: Zollner, Barbara, et al.
Publicado: (2018)

Expert consensus on re-irradiation for recurrent glioma
por: Krauze, Andra, et al.
Publicado: (2017)

Correction to expert consensus on re-irradiation for recurrent glioma
por: Krauze, Andra V., et al.
Publicado: (2018)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
por: Thomas, Alissa, et al.
Publicado: (2018)

Disease progression patterns of bevacizumab responders with recurrent malignant gliomas
por: Kim, Ju-Hwi, et al.
Publicado: (2017)

Hippocampal EUD in primarily irradiated glioblastoma patients
por: Bodensohn, Raphael, et al.
Publicado: (2014)

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma
por: Vordermark, Dirk, et al.
Publicado: (2005)

Choline PET based dose-painting in prostate cancer - Modelling of dose effects
por: Niyazi, Maximilian, et al.
Publicado: (2010)

Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
por: Christ, Sebastian M., et al.
Publicado: (2023)

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
por: Niyazi, Maximilian, et al.
Publicado: (2015)

Stereoscopic X-ray imaging, cone beam CT, and couch positioning in stereotactic radiotherapy of intracranial tumors: preliminary results from a cross-modality pilot installation
por: Zollner, Barbara, et al.
Publicado: (2016)

Re-irradiation alternatives for recurrent high-grade glioma
por: Dong, Yuanli, et al.
Publicado: (2016)

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications
por: Li, Yi, et al.
Publicado: (2017)

Feasibility study on image guided patient positioning for stereotactic body radiation therapy of liver malignancies guided by liver motion
por: Heinz, Christian, et al.
Publicado: (2016)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Re‐irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score—report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK)
por: Combs, Stephanie E., et al.
Publicado: (2018)

Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases
por: Corradini, Stefanie, et al.
Publicado: (2018)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma
por: Kessel, Kerstin A., et al.
Publicado: (2017)

Re-Irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors
por: Lee, Jeongshim, et al.
Publicado: (2016)

LMAP-10 RE-IRRADIATION FOR RECURRENT ADULT DIFFUSE GLIOMA
por: Zhou, Jiangfen, et al.
Publicado: (2023)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
por: Cha, Yongjun, et al.
Publicado: (2017)

Imaging-Based Patterns of Failure following Re-Irradiation for Recurrent/Progressive High-Grade Glioma †
por: Datta, Debanjali, et al.
Publicado: (2023)

FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
por: Carles, Montserrat, et al.
Publicado: (2021)

Outcome of Second Line Treatment of Recurrent High-Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study
por: Anvari, Kazem, et al.
Publicado: (2023)

Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT
por: Niyazi, Maximilian, et al.
Publicado: (2013)

A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG)
por: Amichetti, Maurizio, et al.
Publicado: (2011)

Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
por: Lietke, Stefanie, et al.
Publicado: (2021)

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
por: Burger, Michael C., et al.
Publicado: (2017)

Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)
por: Nagane, Motoo, et al.
Publicado: (2012)

The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma
por: Chan, Joseph, et al.
Publicado: (2020)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas
por: La Rosa, Alonso, et al.
Publicado: (2023)

Surgery vs. radiotherapy in localized prostate cancer. Which is best?
por: Welz, Stefan, et al.
Publicado: (2008)

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4ft3hii6j9idaqslcaqh4s9ssi